Loading clinical trials...

Naked Eye 3D Vision Training for the Prevention and Control of Myopia in Adolescents and Children | Clinical Trials | Clareo Health

UNKNOWNNA

Naked Eye 3D Vision Training for the Prevention and Control of Myopia in Adolescents and Children

NCT05468775•Zhongshan Ophthalmic Center, Sun Yat-sen University

View on ClinicalTrials.gov

Summary

The study used children aged 6-18 as subjects to evaluate the efficacy and safety of naked eye 3D vision training for the prevention and control of myopia in adolescents. A total of 250 subjects were recruited from Zhongshan Ophthalmology Center of Sun Yat-sen University, Shenzhen People's Hospital and Foshan Women's and Children's Hospital, with 1:1 as intervention group and control group. The study assumes that daily naked eye 3D vision training can effectively control the speed of axial elongation and the progression of myopia. The main indicators were the use of optical biometrics to detect the subjects' initial axial length and the axial length after 1 month, 3 months and 6 months of intervention. Secondary indicators were refraction, uncorrected visual acuity, best corrected visual acuity, choroidal thickness, and binocular vision.

Eligibility

Age

6 - 18 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Age 6\~18 years old (including 6 years old and 18 years old), gender is not limited;
•2. Written informed consent signed by the child and legal guardian has been obtained;
•3. Patients who have visited the research center in the past month, diagnosed as myopia according to the "Guidelines for the Prevention and Treatment of Myopia" issued by the General Office of the National Health Commission (Guoweiban Medical Letter \[2018\] No. 393), and the spherical equivalent power is -0.75 to -6.00 Diopter (D) (including -0.75 and -6.00 D);
•4. Astigmatism≤4.00 D, anisometropia≤4.00 D;
•5. Monocular international standard logarithmic visual acuity after spectacle correction ≥20/25;
•6. The subject's guardian can understand the purpose of this study, and the subject can cooperate with the treatment and related eye examinations.

Exclusion Criteria

•1. Any eye of the subject suffers from overt strabismus, or any other pathological changes in the eyeball or acute inflammatory disease of the eye;
•2. Subjects who may suffer from eye diseases that affect vision or refractive errors (such as cataract and other lens damage diseases, glaucoma, macular degeneration, keratopathy, uveitis, retinal detachment, severe vitreous opacity, etc.);
•3. Systemic diseases: those with a history of immune system diseases, central nervous system diseases, Down syndrome, asthma, severe heart and lung function, severe liver and kidney dysfunction;
•4. Binocular hyperopia cannot be corrected to logarithmic visual acuity of 20/25;
•5. The subject has or is undergoing myopia control treatment within the past 1 month, such as atropine eye drops, orthokeratology lenses, progressive lenses, bifocal lenses, etc.;
•6. Photophobia or unable to open eyes normally due to keratitis, trichiasis, trauma, etc. in any eye of the subjects;
•7. Subjects participated in other clinical studies 4 weeks before enrollment;
•8. For safety reasons or the interests of patients, the investigator believes that patients should not participate in other situations in this study.

Key Dates

Start Date

August 1, 2022

Primary Completion Date

October 1, 2022

Completion Date

October 1, 2022

Last Updated

July 21, 2022

Enrollment

250

ESTIMATED participants

Conditions

Adolescents and ChildrenAxial ElongationNaked Eye 3D Vision TrainingVisual Function

Interventions

Naked eye 3D vision training

BEHAVIORAL

Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia

NCT03381079

High MyopiaPosterior Scleral Reinforcement+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions